TP53 and B-cell chronic lymphocytic leukemia: Another study explained the link between O-GlcNAcylation and the indolent clinical behavior of CLL (Lode et al. 2016; Yang et al. 2006): O-GlcNAcylation of p53 at Ser149 can inhibit cancer progression by stabilizing wild-type p53 and activating the intact p53 pathway.